BerGenBio

Selective AXL inhibitors

Home  /  Media Centre  /  Presentations

SITC 2020, Professor James Spicer, PhD, FRCP

Share This Presentation

11 November 2020

A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab, in pts with previouslytreated advanced NSCLC: Updated clinical & translational analysis

 

Share This Presentation

Latest News

News

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

News

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.